As of Feb 12
| +0.02 / +0.47%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 32.00, with a high estimate of 41.00 and a low estimate of 19.00. The median estimate represents a +647.66% increase from the last price of 4.28.
The current consensus among 5 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.